



## Oesogastric Cancer: Treatment and Management

Guest Editor:

**Dr. Arnaud Pasquer**

Service de Chirurgie Digestive,  
CHU Lyon, Lyon, France

Deadline for manuscript  
submissions:

**31 December 2024**

### Message from the Guest Editor

Dear Colleagues,

Despite recent advances in the management of oesogastric cancers through the optimization of chemotherapy and radiotherapy protocols and surgical procedures, these cancers remain fatal in a large number of situations, with an average survival of 16% at 5 years. One-third of patients are operable at the time of diagnosis.

This Special Issue aims to show the precise impact of the most recent evolutions in terms of operative techniques in initial or recurrence settings, for example, the contribution of minimally invasive surgery—including thoracic approaches—on the quality of the lymph node resection, its extension, survival data, etc.

- Investigate the possibilities of improving the postoperative course in vulnerable patients by medical or interventional perioperative optimization according to comorbidities.
- Describe the surgical possibilities, novelties, and limits in the situation of peritoneal carcinosis.
- Evaluate the contribution of new chemotherapy/immunotherapy/radiotherapy protocols.
- Explore the management of complete responders.

I look forward to receiving your contributions.

Dr. Arnaud Pasquer

*Guest Editor*





# cancers



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

## Contact Us

*Cancers* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
X@Cancers\_MDPI